Dr Mendes Bastos addressed the heterogeneity of atopic dermatitis patients, causes, and therapy options, and the ongoing research to address them.
Clinically meaningful improvements in Eczema Area and Severity Index (EASI) were observed with amlitelimab treatment for atopic dermatitis.
Skin tape stripping is an effective, non-invasive way to detect biomarkers associated with early disease in hidradenitis suppurativa.
Excluding severe AA, 83–93% of participants in the ALLEGRO-LT trial reached an 80% re-growth of scalp hair or more after 15 months of treatment.
A cohort study from the BADBIR registry revealed that IL-23p19 inhibitors are associated with the highest drug survival regarding effectiveness and safety.
Continuing povorcitinib treatment after a 6-month double-blind phase led to additional repigmentation for many participants of a vitiligo phase 2b trial.
In a small study, treating different severe hand eczemas with dupilumab led to favourable results. At week 16, 19 of 20 participants reached HECSI75.
Extended treatment with ruxolitinib cream resulted in substantial response rates in patients who had demonstrated no or little response after 6 months.
Long-term conventional systemic therapies lead to higher drug-related adverse events and treatment discontinuation rates compared with biologics.
The agent led to remarkable clinical responses for hidradenitis suppurative in the phase 2 MIRA trial. It was relatively well tolerated without new safety signals.
Upadacitinib therapy led to robust clinical efficacy and itch relief in adolescents and adults with moderate-to-severe atopic dermatitis in 3 ongoing phase 3 trials.
Nemolizumab achieved the 2 primary endpoints in the phase 3 OLYMPIA 1 study for itch and Investigator’s Global Assessment success in prurigo nodularis.
A pooled analysis found that secukinumab treatment entailed a numerically greater pain reduction than placebo in patients with hidradenitis suppurativa.
Twice-daily treatment with a plant extracts solution led to sustained hair regrowth in children and adolescents with alopecia areata in the phase 2/3 RAAINBOW trial.
Phase 3 results show its potential as a new agent for atopic dermatitis from early age. Over 45% of participants met the primary endpoint of clear or almost clear skin.
Over 5 million people globally suffer geographic atrophy linked to age-related macular degeneration. A new intravitreal drug was approved for its treatment.
Tattoos are becoming increasingly popular, but these permanent body ornaments can cause considerable damage to the skin.
Some retrospective studies suggested that combination of PPIs with immuno-chemotherapies, is associated with worse outcomes. What's new on this issue?
A 47-year-old female patient complains of an episode of fainting and unwanted weight loss, in addition to gastrointestinal issues. Could you guess a diagnosis?
Athletes often treat cramps themselves, but the effectiveness of untargeted therapy is questionable. What helps with painful attacks and what doesn't?